Evidence map›Paper›PMID 28518224›Full record

ArticleClinical and experimental immunology2017

T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum.

E Antiga, R Maglie, W Volpi, B Bianchi, E Berti, A V Marzano, M Caproni

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Lesional pruritus in pyoderma gangrenosum: Present but not predominant.JID innovations : skin science from molecules to population health · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Skin Manifestation Induced by Immune Checkpoint Inhibitors.Clinical, cosmetic and investigational dermatology · 2022
    Review
  16. Article
  17. Review
  18. Review
  19. Pyoderma gangrenosum.Nature reviews. Disease primers · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

E AntigaDepartment of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, Italy.ORCID 0000-0001-7787-4433
R MaglieDepartment of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, Italy.
W VolpiDepartment of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, Italy.
B BianchiDepartment of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, Italy.
E BertiDermatology Unit, Department of Pathophysiology and Transplantation, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
A V MarzanoDermatology Unit, Department of Pathophysiology and Transplantation, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
M CaproniDepartment of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, Italy.
University of Florence · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyoderma gangrenosum (PG) is a rare, immune-mediated skin disease classified into the group of neutrophilic dermatoses. Although a number of studies confirmed the central role of innate immunity, only few studies have investigated the possible contributing role of acquired immunity. In particular, no reports concerning T helper type 1 (Th1) and Th2 cells are available as yet. Therefore, 15 patients with PG, five with Sweet's syndrome (SS) and nine skin specimens from healthy controls (HC) were investigated, evaluating the expression of Th1-related markers interleukin (IL)-12, interferon (IFN)-γ, C-X-C motif chemokine receptor 3 (CXCR3) and C-C motif chemokine receptor 5 (CCR5), of the Th2-related molecules IL-4, IL-5, IL-13 and CCR3, of the co-stimulatory axis CD40/CD40 ligand, of IL-15 and the natural killer (NK) cell marker CD56 in skin lesions by immunohistochemistry. Patients with PG and SS showed a higher expression of Th1 markers than HC. Conversely, IL-5- and CCR3-expressing cells were less numerous in PG skin lesions compared to SS (P = 0·0157 and < 0·0001, respectively). Both CD40 and CD40L were expressed more in PG than in SS and HC (P < 0·0001 for both). Finally, the number of IL-15

Indexed as

AdultAgedCD40 LigandCD56 AntigenFemaleHumansInterferon-gammaInterleukin-12Interleukin-13Interleukin-15Interleukin-4Interleukin-5MaleMiddle AgedPyoderma GangrenosumReceptors, CCR3CCR3 protein, humanCCR5 protein, humanCD40 LigandCD56 AntigenCXCR3 protein, humanIL13 protein, humanIL15 protein, humanIL4 protein, humanIL5 protein, humanInterferon-gammaInterleukin-12Interleukin-13Interleukin-15Interleukin-4Interleukin-5NCAM1 protein, humanReceptors, CCR3Receptors, CCR5Receptors, CXCR3Autoinflammatory diseaseschemokinescytokinesskinTh1/Th2 cells

Identifiers

PMID28518224
PMCPMC5543499
OpenAlexW2614718560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.